Search Results
Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland
Search for other papers by Luca Giovanella in
Google Scholar
PubMed
Search for other papers by Maria Luisa Garo in
Google Scholar
PubMed
Search for other papers by Domenico Albano in
Google Scholar
PubMed
Search for other papers by Rainer Görges in
Google Scholar
PubMed
Faculty of Biomedical Sciences, Institute of Oncology Research, Università della Svizzera Italiana, Bellinzona, Switzerland
Search for other papers by Luca Ceriani in
Google Scholar
PubMed
independently assessed the risk of bias of included studies using the NIH quality assessment tool for observational cohorts ( https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools ). The tool comprises 14 criteria; the overall assessment is
Department of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands
Search for other papers by Josephina G Kuiper in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Search for other papers by Aline C Fenneman in
Google Scholar
PubMed
Search for other papers by Anne H van der Spek in
Google Scholar
PubMed
Search for other papers by Elena Rampanelli in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
Search for other papers by Max Nieuwdorp in
Google Scholar
PubMed
Search for other papers by Myrthe P P van Herk-Sukel in
Google Scholar
PubMed
Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands
Search for other papers by Valery E P P Lemmens in
Google Scholar
PubMed
Search for other papers by Ernst J Kuipers in
Google Scholar
PubMed
Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, Netherlands
Search for other papers by Ron M C Herings in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
. However, it is unlikely that a large proportion of our study population had untreated overt thyroid disease during the available observation period of 7.3 years. A recent cohort study from the Netherlands showed that only 0.44% of their study population
Search for other papers by Kazhan Mollazadegan in
Google Scholar
PubMed
Search for other papers by Britt Skogseid in
Google Scholar
PubMed
Search for other papers by Johan Botling in
Google Scholar
PubMed
Search for other papers by Tobias Åkerström in
Google Scholar
PubMed
Search for other papers by Barbro Eriksson in
Google Scholar
PubMed
Search for other papers by Staffan Welin in
Google Scholar
PubMed
Search for other papers by Anders Sundin in
Google Scholar
PubMed
Search for other papers by Joakim Crona in
Google Scholar
PubMed
group. Methods The study was approved by the Ethical Review Board in Uppsala (reference ID: 2015/544). Patients provided written informed consent. The study is reported according to the Strengthening the Reporting of Observational Studies in
Search for other papers by Orwa Dandash in
Google Scholar
PubMed
Search for other papers by James Allebone in
Google Scholar
PubMed
Search for other papers by Adam Mirabelli in
Google Scholar
PubMed
Search for other papers by Nicholas Russell in
Google Scholar
PubMed
Search for other papers by Mathis Grossmann in
Google Scholar
PubMed
Department of Florey Institute, University of Melbourne, Parkville, Victoria, Australia
Search for other papers by Andrea Gogos in
Google Scholar
PubMed
Search for other papers by Richard A Kanaan in
Google Scholar
PubMed
on our previous investigation in this group ( 32 ) and results from other observational studies investigating changes in fat mass after 6 months of ADT ( 34 ), we used a conservative difference of 4.3% and s.d. of 7.1% that yielded 43 participants
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed
Search for other papers by Satish S Kumar in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Khyatisha Seejore in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Harpal Randeva in
Google Scholar
PubMed
Leeds Institute of Medical Research, University of Leeds, UK
Search for other papers by Adam Glaser in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Search for other papers by Georgina Gerrard in
Google Scholar
PubMed
Search for other papers by Carmel Loughrey in
Google Scholar
PubMed
Search for other papers by Ahmed Al-Qaissi in
Google Scholar
PubMed
Search for other papers by Ramzi Ajjan in
Google Scholar
PubMed
Search for other papers by Julie Lynch in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
the primary disease; however, an increase in cardiovascular mortality ( 3 ) and risk of early and late-occurring stroke ( 4 , 5 ) are also observed. There are limited cross-sectional studies evaluating conventional vascular risk factors in SCBT ( 6
Search for other papers by Peiwen Wu in
Google Scholar
PubMed
Search for other papers by Dongjie He in
Google Scholar
PubMed
Search for other papers by Hao Chang in
Google Scholar
PubMed
Search for other papers by Xiaozhi Zhang in
Google Scholar
PubMed
). The institutional review board deemed that this study could be exempted from review and informed consent because the data used in the study were freely available. This study followed the Strengthening the Reporting of Observational Studies in
Search for other papers by Enrique Pedernera in
Google Scholar
PubMed
Search for other papers by Flavia Morales-Vásquez in
Google Scholar
PubMed
Search for other papers by María J Gómora in
Google Scholar
PubMed
Search for other papers by Miguel A Almaraz in
Google Scholar
PubMed
Universidad La Salle, Posgrado de la Facultad de Ciencias Químicas, Ciudad de México, México
Search for other papers by Esteban Mena in
Google Scholar
PubMed
Search for other papers by Delia Pérez-Montiel in
Google Scholar
PubMed
Search for other papers by Elizabeth Rendon in
Google Scholar
PubMed
Search for other papers by Horacio López-Basave in
Google Scholar
PubMed
Search for other papers by Juan Maldonado-Cubas in
Google Scholar
PubMed
Search for other papers by Carmen Méndez in
Google Scholar
PubMed
during the first 2 years of follow-up, gradually diverging in the long term, while remaining statistically significant throughout the study. The observation suggests that the protective effect of 17β-HSD1 is evident in less aggressive tumors. Furthermore
Search for other papers by Kaili Yang in
Google Scholar
PubMed
Search for other papers by Jiarui Li in
Google Scholar
PubMed
Search for other papers by Yuejuan Cheng in
Google Scholar
PubMed
Search for other papers by Chunmei Bai in
Google Scholar
PubMed
landscape and chronological changes of clinical trials in GEP-NENs. This study was conducted according to the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) guideline and was exempt from institutional board review because it
Search for other papers by Margarida Brito in
Google Scholar
PubMed
Search for other papers by Susana Prazeres in
Google Scholar
PubMed
Search for other papers by Marta Malheiros in
Google Scholar
PubMed
single-center, observational study with retrospective data collection, separated into two parts. Initially, four samples of serum with low estradiol levels, obtained from our laboratory serum bank, were spiked with fulvestrant at various concentrations. A
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Garvan Institute of Medical Research, New South Wales, Australia
School of Medical Sciences, University of New South Wales, New South Wales, Australia
Search for other papers by Vita Birzniece in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Department of Diabetes and Endocrinology, Westmead Hospital, New South Wales, Australia
Search for other papers by Teresa Lam in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Search for other papers by Mark McLean in
Google Scholar
PubMed
Search for other papers by Navneeta Reddy in
Google Scholar
PubMed
Department of Diabetes and Endocrinology, Blacktown Hospital, New South Wales, Australia
Search for other papers by Haleh Shahidipour in
Google Scholar
PubMed
Faculty of Medicine, Health and Human Sciences, Macquarie University, New South Wales, Australia
Crown Princess Mary Cancer Centre, Westmead Hospital, New South Wales, Australia
Search for other papers by Amy Hayden in
Google Scholar
PubMed
Search for other papers by Howard Gurney in
Google Scholar
PubMed
Search for other papers by Glenn Stone in
Google Scholar
PubMed
Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Steno Diabetes Center Odense, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Rikke Hjortebjerg in
Google Scholar
PubMed
Endocrine Research Unit, Department of Endocrinology, Odense University Hospital & Department of Clinical Research, Faculty of Health, University of Southern Denmark, Odense, Denmark
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
cancer patients. An important observation of this study is the reduction in IGF-2 during metformin treatment. IGF signalling drives cancer development and progression ( 22 ). IGF-2 shares structural similarity to insulin and in fact is a more potent